Adaptive Biotechnologies Corporation (ADPT) Stock Forecast
Data as of May 2, 2026Healthcare · Current price $14.18 (+0.57%)
Price Target Range
Consensus Price Target Over Time
Analyst Rating Distribution
Last 3 Months
6-Month Trend
Latest Analyst Forecasts
Price targets issued by Wall Street analysts. Upside calculated against today's price.
| Date | Analyst | Firm | Price Target | Upside |
|---|---|---|---|---|
| Feb 6, 2026 | Sebastian Sandler | Piper Sandler | $21.00 | +48.1% |
| Dec 1, 2025 | Kallum Titchmarsh | Morgan Stanley | $21.00 | +48.1% |
| Apr 4, 2024 | Mark Massaro | BTIG | $5.00 | -64.7% |
| Dec 21, 2022 | David Westenberg | Piper Sandler | $14.00 | -1.3% |
| Aug 17, 2022 | David Westenberg | Piper Sandler | $12.00 | -15.4% |
| Jun 13, 2022 | David Westenberg | Piper Sandler | $7.50 | -47.1% |
Top Analysts Covering ADPT
ADPT vs Sector & Market
| Metric | ADPT | Healthcare Avg | Large Cap Avg |
|---|---|---|---|
| Analyst Rating | 2.17 | 2.24 | 2.41 |
| Analyst Count | 6 | 8 | 18 |
| Target Upside | +49.9% | +1150.2% | +14.9% |
| P/E Ratio | -36.13 | 6.90 | 31.19 |
Revenue Estimates
| Period | Low | Avg | High | # |
|---|---|---|---|---|
| 2026-12-31 | $279M | $282M | $286M | 7 |
| 2027-03-31 | $73M | $75M | $80M | 3 |
| 2027-06-30 | $80M | $82M | $86M | 3 |
| 2027-09-30 | $84M | $87M | $91M | 3 |
| 2027-12-31 | $98M | $101M | $106M | 3 |
| 2028-03-31 | $88M | $91M | $96M | 2 |
| 2028-06-30 | $95M | $98M | $103M | 2 |
| 2028-09-30 | $101M | $104M | $109M | 2 |
| 2028-12-31 | $123M | $127M | $134M | 2 |
| 2029-12-31 | $497M | $505M | $513M | 3 |
| 2030-12-31 | $631M | $641M | $651M | 3 |
EPS Estimates
| Period | Low | Avg | High | # |
|---|---|---|---|---|
| 2026-12-31 | $-0.50 | $-0.48 | $-0.46 | 6 |
| 2027-03-31 | $-0.12 | $-0.12 | $-0.11 | 1 |
| 2027-06-30 | $-0.09 | $-0.09 | $-0.08 | 1 |
| 2027-09-30 | $-0.07 | $-0.06 | $-0.06 | 1 |
| 2027-12-31 | $-0.02 | $-0.02 | $-0.01 | 1 |
| 2028-03-31 | $-0.06 | $-0.06 | $-0.06 | 2 |
| 2028-06-30 | $-0.01 | $-0.01 | $-0.01 | 2 |
| 2028-09-30 | $0.03 | $0.03 | $0.03 | 2 |
| 2028-12-31 | $0.09 | $0.09 | $0.10 | 2 |
| 2029-12-31 | $0.08 | $0.09 | $0.09 | 2 |
| 2030-12-31 | $-0.01 | $-0.01 | $-0.01 | 2 |
Frequently Asked Questions
What is the analyst consensus for ADPT?
The consensus among 6 analysts covering Adaptive Biotechnologies Corporation (ADPT) is Buy with an average price target of $21.25.
What is the highest price target for ADPT?
The highest price target for ADPT is $21.00, set by Sebastian Sandler at Piper Sandler on 2026-02-06.
What is the lowest price target for ADPT?
The lowest price target for ADPT is $5.00, set by Mark Massaro at BTIG on 2024-04-04.
How many analysts cover ADPT?
6 analysts have issued ratings for Adaptive Biotechnologies Corporation in the past 12 months.
Is ADPT a buy or sell right now?
Based on 6 analyst ratings, ADPT has a consensus rating of Buy (2.17/5) with a +49.9% upside to the consensus target of $21.25.
What are the earnings estimates for ADPT?
Analysts estimate ADPT will report EPS of $-0.48 for the period ending 2026-12-31, with revenue estimated at $282M.
Related Stock Forecasts
Data updated daily. Analyst price targets sourced from public filings and broker reports. Not investment advice.